UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/805,099	03/19/2004	Chunhui Xu	099/004P	7715
22869 GERON CORP	7590 03/18/200 ^o ORATION	9	EXAMINER	
Attn. David J. E	-		NOBLE, MARCIA STEPHENS	
230 CONSTITUTION DRIVE MENLO PARK, CA 94025			ART UNIT	PAPER NUMBER
			1632	
			MAIL DATE	DELIVERY MODE
			03/18/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/805,099	XU ET AL.				
Office Action Summary	Examiner	Art Unit				
	MARCIA S. NOBLE	1632				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on <u>25 N</u>	lovember 2008					
· -	· 					
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
	application					
	Claim(s) <u>1-4,6,7,9 and 10</u> is/are pending in the application.					
5) Claim(s) is/are allowed.	4a) Of the above claim(s) is/are withdrawn from consideration.					
·— · · · ——						
	Claim(s) <u>1-4,7 and 10</u> is/are rejected.					
7) Claim(s) 6 and 9 is/are objected to.						
8) Claim(s) are subject to restriction and/c	or election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine	er.					
10)⊠ The drawing(s) filed on <u>15 November 2004</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal P					
Paper No(s)/Mail Date <u>5/8/2008, 11/25/2008, &1/12/2009</u> .	6) Other:	••				



Application No.

Art Unit: 1632

DETAILED ACTION

Status of Claims

1. Claims 1-4, 6, 7, 9, and 10 are pending. Claims 1 is amended, by the amendment filed 11/25/2008. Claims 1-4, 6, 7, 9, and 10 are under consideration.

Withdrawn Rejections

- 2. (a) The rejection of claims 1-4, 6, 7, 9, and 10, under 35 U.S.C. 103(a) as being unpatentable over Doevendans et al (J Mol Cell Cardiol 32:839-851, 2000, of record), in view of Schuldiner et al (PNAS 97(21):11307-11312, 2000; of record), Sugi and Lough (Dev Biol 168:567-574, 1995; of record), Thomson et al (Science 282:1145-1147, 1998), and Nair and Nair (Indain J Exp Biol 35(5):451-456, 1997), as set forth in the Office Action, mailed 6/25/2008 (pp. 6-10), is withdrawn. The claims recite isolating the cell factions based upon cardiac specific markers, which is not taught by the art of record. Therefore, the rejection is withdrawn.
- (b) The provisional rejection of claims 1, 2, 4, and 7 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5 and 8-12 of copending Application No. 11/086,709, as set forth in the Office Action, mailed 6/25/2008, p. 4), is withdrawn. The copending claims recite without EB formation. Therefore, the claims no longer encompass the same limitations and the rejection is withdrawn.

Double Patenting

Art Unit: 1632

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1-4, 7, and 10 stand provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-10, 12-18, and 20 of copending Application No. 11/040691

Applicant states that the instant rejection is provisional and if copending application becomes allowable prior to allowance of the current claims, Applicant will address the rejection on their merits or will file a terminal disclaimer. Applicant's statement is acknowledged and the rejection is maintained.

Claim Objections

Art Unit: 1632

4. Claims 6 and 9 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

5. No claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marcia S. Noble whose telephone number is (571) 272-5545. The examiner can normally be reached on M-F 9 to 5:30.

Art Unit: 1632

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Deborah Crouch/ Primary Examiner, Art Unit 1632

Marcia S. Noble AU 1632